Nephros, Inc. (NEPH) is a leading U.S. medical device company that develops and sells high-quality liquid purification filters and solutions. The company focuses mainly in the healthcare sector, where it provides essential solutions to hospitals and medical facilities for producing ultra-pure water, necessary for a variety of medical therapeutic and diagnostic applications.
Founded in 1997 and headquartered in South Orange, New Jersey, Nephros has become a respected name in the medical device field for its innovative product line and commitment to quality. The company has two operational units, namely the Nephros Therapeutic Technologies that focus on the design and development of medical devices, and the Nephros Pathogen Detection and Elimination Unit which develops technologies for detecting and eliminating harmful pathogens in water.
The company's flagship product is the HDF (Hemodiafiltration) system, an innovative device that provides a superior dialysis modality for patients with end-stage renal disease (ESRD). Compared to standard hemodialysis, this system filters out more harmful waste products, leading to improved patient outcomes.
Furthermore, Nephros has a range of filtration products under its line, which are used widely in hospital infection control, medical device reprocessing, commercial facilities, etc. These products remove contaminants from water, ensuring safe water supply, which is particularly crucial for immunocompromised patients in hospital settings.
Nephros's business model integrates research, development, manufacturing, and marketing operations, providing effective, efficient, and comprehensive services to its clients. The company's focus on both technological innovation and quality control has distinguished it in the medical device industry, making it a trusted partner of healthcare providers across the globe.
Nephros Inc. is publicly traded on the OTC Market Group's OTCQB venture market place, under the symbol "NEPH."The company's growth strategy is a combination of organic growth, strategic alliances, and acquisitions to enhance its product portfolio and market coverage.
In conclusion, Nephros Inc. is a pioneer in the field of water purification and filtration systems in the medical device sector. With a strong commitment to improve the quality of patient care, the company continues its endeavors of enhancing its technology to maintain its market leadership and contribute to better healthcare outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nephros Inc. reported record Q2 2026 revenue of $6 million, a 36% year-over-year increase, driven by double-digit growth in programmatic product revenue and nearly tripled service-only revenue. The company achieved a 67% gross margin, significantly boosted by a $600,000 tariff refund, and saw net income surge over 400% to $1.2 million, with adjusted EBITDA up 260% to $1.3 million. Nephros is expanding its integrated water safety platform, diversifying revenue streams, and investing in new products for emerging water quality concerns while maintaining a strong, debt-free cash position.
NEPHROS INC director Amron Arthur H executed transactions involving 43,295 shares of the company stock across three trades on September 14, 2026. The share prices ranged from $0 to $3.95, and these transactions were reported under SEC transaction code J. Following these trades, Amron Arthur H's total ownership in NEPHROS INC stands at 25,546 shares.
Nephros, Inc. reported record Q2 2026 revenue of $6.0M, a 36% year-over-year increase, and significantly higher profitability, with net income rising over 400%. The company emphasized strong operational execution and long-term growth confidence, despite facing margin pressures from tariffs, foreign exchange, and freight costs, and acknowledged that a one-time tariff refund boosted gross margins. Weak operating cash flow due to increased accounts receivable and inventory, along with rising operating expenses for growth, were also noted.
Nephros (NEPH) reported record Q2 2026 revenue of $6 million, a 36% increase year-over-year, driven by strong growth in core programmatic revenue and a nearly threefold increase in service revenue. The company's net income rose to $1.2 million, significantly boosted by a $600,000 tariff refund, though underlying margins are still affected by tariffs and currency fluctuations. Nephros is expanding its integrated water safety platform, focusing on products, services, and education, with new offerings addressing PFAS and nanoplastics, and aims to sustain growth through high customer retention and strategic investments.
This article highlights three promising penny stocks for August 2026: Nephros (NEPH), Siebert Financial (SIEB), and Douglas Elliman (DOUG). It examines their financial health, recent performance, and strategic initiatives, noting that these companies offer potential for growth despite being smaller or newer entities. The piece aims to guide investors toward hidden value in quality companies within the robust U.S. market.